National Cancer Institute Selects ICF for Epidemiology and Genetics Research IDIQ
ICF Selected for NIH Contract
ICF has been awarded a significant contract by the NIH's National Cancer Institute to provide clinical operations support for cancer epidemiology studies. The contract, valued at $320 million over 10 years, will enhance ICF's role in public health research. Their team, comprising around 150 specialists, will conduct various epidemiologic studies globally. This partnership underscores ICF's expertise in supporting health research initiatives, aligning with its mission to inform cancer prevention efforts.
- Awarded a $320 million contract with a 10-year term, enhancing revenue potential.
- Brings a team of approximately 150 specialists to support NIH's cancer research initiatives, boosting operational capabilities.
- Establishes a long-term partnership with the NIH, reinforcing ICF's reputation in public health and epidemiology.
- Dependence on government contracts may pose risks related to funding stability and procurement processes.
Company Will Compete for up to
FAIRFAX, Va., Aug. 15, 2022 /PRNewswire/ -- The National Institutes of Health (NIH) National Cancer Institute's (NCI) Division of Cancer Epidemiology and Genetics (DCEG) recently selected global consulting and digital services provider ICF (NASDAQ:ICFI) as one of five awardees for a new multiple-award indefinite delivery, indefinite quantity (IDIQ) contract to provide epidemiologic and clinical operations support for studies and other research activities.
The IDIQ, which was awarded in the second quarter of 2022, has a ceiling value of
ICF's team of health research and public health experts will support DCEG's programs, and its approximately 150 epidemiologists, geneticists and biostatisticians, in three key areas: field preparation and study management, exposure assessment and clinical support. This will include simultaneously managing concurrent multidisciplinary domestic and international epidemiologic and genetic studies of varying sizes and complexity.
"ICF has a long history of supporting NIH's epidemiologic and clinical research programs with technical expertise in scientific and survey research operations, statistical data management, digital modernization of data collection systems and more," said Mark Lee, executive vice president and public sector lead. "We are excited to bring all of these skills to support DCEG in meeting its mission—to discover the causes of cancer and inform future prevention."
For over 40 years, ICF has supported U.S. Department of Health and Human Services clients across all divisions with comprehensive services in public health, epidemiology, survey research, genetics, biostatistics, clinical informatics, digital modernization and more.
ICF combines deep domain and scientific expertise with leading-edge technology solutions to help public health clients address their greatest challenges and design solutions that increase understanding of disease causation and improve outcomes for all populations. ICF is also a leading provider of low-code, open-source and cloud-native solutions, which enables the company to provide customers with flexible applications and tools in a cost-effective environment.
Read more about ICF's federal health and digital modernization services.
About ICF
ICF is a global consulting services company with approximately 8,000 full- and part-time employees, but we are not your typical consultants. At ICF, business analysts and policy specialists work together with digital strategists, data scientists and creatives. We combine unmatched industry expertise with cutting-edge engagement capabilities to help organizations solve their most complex challenges. Since 1969, public and private sector clients have worked with ICF to navigate change and shape the future. Learn more at icf.com.
Caution Concerning Forward-looking Statements
Statements that are not historical facts and involve known and unknown risks and uncertainties are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such statements may concern our current expectations about our future results, plans, operations and prospects and involve certain risks, including those related to the government contracting industry generally; our particular business, including our dependence on contracts with U.S. federal government agencies; our ability to acquire and successfully integrate businesses; and the effects of the novel coronavirus disease (COVID-19) and related federal, state and local government actions and reactions on the health of our staff and that of our clients, the continuity of our and our clients' operations, our results of operations and our outlook. These and other factors that could cause our actual results to differ from those indicated in forward-looking statements that are included in the "Risk Factors" section of our securities filings with the Securities and Exchange Commission. The forward-looking statements included herein are only made as of the date hereof, and we specifically disclaim any obligation to update these statements in the future.
Contact: Lauren Dyke, lauren.dyke@ICF.com, +1.571.373.5577
View original content to download multimedia:https://www.prnewswire.com/news-releases/national-cancer-institute-selects-icf-for-epidemiology-and-genetics-research-idiq-301605795.html
SOURCE ICF
FAQ
What is the value of the contract awarded to ICF by the NIH?
What services will ICF provide under the NIH contract?
How long is the contract duration for ICF's work with the NIH?
What is the significance of ICF's contract with the NIH?
When was the contract awarded to ICF?
